DIAMEDICA THERAPEUTICS INC (DMAC) Stock News
NASDAQ:DMAC - Nasdaq - CA25253X2077 - Common Stock - Currency: USD
DMAC Latest News, Press Relases and Analysis
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips DiaMedica Therapeutics (NASDAQ:DMAC) just reported results for the second quart...
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips DiaMedica Therapeutics (NASDAQ:DMAC) just reported results for the first quarte...
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips DiaMedica Therapeutics (NASDAQ:DMAC) just reported results for the fourth quart...
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
DiaMedica Therapeutics Upcoming Conference Participation
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
DiaMedica Therapeutics Announces $11.8 Million Private Placement
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023.
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
DiaMedica Therapeutics names Masuoka as its chief medical officer (NASDAQ:DMAC)
DiaMedica Therapeutics appoints Lorianne Masuoka as its chief medical officer, bringing over 20 years of experience in the pharmaceutical industry.
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we're offering all the details that investors need to know about this morning.
